Despite growing commercial interest in antimicrobial strategies that rely on antibodies, recent clinical trial failures suggest they are a work in progress.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout

CNRI/Photo Researchers, Inc.
References
Eash, S. Pharmacor, Infectious Disease, Study #2 2006 Decision Resources, Waltham, MA (2006) in press.
Projan, S.J., Nesin, M. & Dunman, P.M. Curr. Opin. Pharmacol. 6, 473–479 (2006).
Pirofski, L.A. & Casadevall, A. Curr. Opin. Microbiol. 9, 489–495 (2006).
Casadevall, A. Clin. Infect. Dis. 42, 1414–1416 (2006).
Author information
Authors and Affiliations
Related links
Rights and permissions
About this article
Cite this article
Baker, M. Anti-infective antibodies: finding the path forward. Nat Biotechnol 24, 1491–1493 (2006). https://doi.org/10.1038/nbt1206-1491
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1206-1491
This article is cited by
-
Anti-infective monoclonals step in where antimicrobials fail
Nature Biotechnology (2013)
-
The contribution of immunology to the rational design of novel antibacterial vaccines
Nature Reviews Microbiology (2007)